Phase 2 Alzheimer's Disease Trial, Recruiting NCT05374278 Sponsor: David Wilson Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT05374278
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 40 and 75 years old
  • Your body weight (BMI) is within a normal range for your age
  • You are able to read and sign a consent form agreeing to follow the study's requirements, or you have a legally recognized guardian who can do this on your behalf
  • You do not have any obvious physical health conditions
  • You have a suitable artery in your wrist or arm that can be used for a small medical procedure (confirm with trial site)
  • You are a non-smoker and are not currently using any over-the-counter nicotine replacement products (such as patches or gum)
  • You have not taken any prescription medications that affect the brain or nervous system for at least three weeks

For certain groups within the trial (Cohorts 2B and 2C) only:

  • You have someone (such as a family member, partner, friend, or caregiver) who spends at least 5 hours per week with you, knows your daily routines, and can attend all study visits with you
  • You have had a specific memory and thinking assessment (called an MME) within the last 6 months (confirm with trial site)

Who may not be able to join:

  • You are unable or unwilling to sign a consent form and do not have a guardian who can do so for you
  • The arteries in your wrist or arm are not suitable for the procedure required in the study
  • You have recently had another radioactive imaging scan (such as a PET scan) and there is still too much radiation remaining in your body, or you have had more than two PET scans in the past two weeks (confirm with trial site)
  • Taking part would mean you have had more than 3 PET scans in total within one year
  • You cannot have an MRI scan — for example, because you have a permanent pacemaker, metal implants in your body, or you have severe claustrophobia
  • You are currently pregnant (women who could become pregnant will be tested before the scan, and a positive result would mean you cannot join)
  • You are currently breastfeeding
  • You have a medical condition or personal circumstances that the study doctors believe would make it difficult to get reliable results or safely complete the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: David Wilson, MD, PhD, University of California, San Francisco

Phone: 415-514-6229

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
David Wilson
Registry
ClinicalTrials.gov
Start date
2 November 2021
Est. completion
3 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety of Administered dose; Dosimetry of [18F]RP-115; Biodistribution of [18F]RP-115

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov